EU agency backs Pfizer leukaemia drug

LONDON Fri Jan 18, 2013 7:37am EST

LONDON Jan 18 (Reuters) - The European Medicines Agency on Friday recommended approval of Pfizer's new pill for a rare type of leukaemia, Bosulif, in a fresh boost for the U.S. drugmaker's cancer business.

Recommendations for marketing approval by the agency's Committee for Medicinal Products for Human Use (CHMP) are normally endorsed by the European Commission within a couple of months.